Insider Transactions in Q1 2018 at Merck & Co., Inc. (MRK)
Insider Transaction List (Q1 2018)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
34,094
+50.0%
|
$1,841,076
$54.72 P/Share
|
|
Feb 27
2018
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
110,393
+13.44%
|
$5,961,222
$54.72 P/Share
|
|
Feb 27
2018
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
34,931
+20.09%
|
$1,886,274
$54.72 P/Share
|
|
Feb 27
2018
|
Ashley Watson SVP Chief Ethics & Com Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,322
+50.0%
|
$125,388
$54.72 P/Share
|
|
Feb 27
2018
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Grant, award, or other acquisition
|
Direct |
13,949
+11.78%
|
$753,246
$54.72 P/Share
|
|
Feb 27
2018
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
4,522
+8.58%
|
$244,188
$54.72 P/Share
|
|
Feb 27
2018
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,062
+14.09%
|
$489,348
$54.72 P/Share
|
|
Feb 27
2018
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
12,575
+18.5%
|
$679,050
$54.72 P/Share
|
|
Feb 27
2018
|
Michael J Holston EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
20,694
+22.87%
|
$1,117,476
$54.72 P/Share
|
|
Feb 27
2018
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
30,908
+22.55%
|
$1,669,032
$54.72 P/Share
|
|
Feb 27
2018
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
3,090
+13.86%
|
$166,860
$54.72 P/Share
|
|
Feb 09
2018
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Payment of exercise price or tax liability
|
Direct |
2,974
-6.5%
|
$160,596
$54.73 P/Share
|
|
Feb 09
2018
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
8,572
+15.77%
|
-
|
|
Feb 09
2018
|
Wendell P Weeks Director |
SELL
Open market or private sale
|
Direct |
5,000
-98.04%
|
$265,000
$53.57 P/Share
|
|
Feb 09
2018
|
Wendell P Weeks Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
$190,000
$38.04 P/Share
|
|
Jan 16
2018
|
Michael J Holston EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
12,500
-20.29%
|
$762,500
$61.63 P/Share
|
|
Jan 16
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Indirect |
50,608
-44.64%
|
$3,087,088
$61.63 P/Share
|
|
Jan 16
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
50,994
-100.0%
|
$3,110,634
$61.63 P/Share
|
|
Jan 16
2018
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
50,994
+50.0%
|
$1,835,784
$36.56 P/Share
|
|
Jan 16
2018
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
60,000
-20.48%
|
$3,660,000
$61.63 P/Share
|
|
Jan 16
2018
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Exercise of conversion of derivative security
|
Direct |
52,000
+25.31%
|
$2,288,000
$44.3 P/Share
|
|
Jan 12
2018
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Open market or private sale
|
Direct |
5,000
-4.7%
|
$290,000
$58.0 P/Share
|